Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

St. Jude Medical Inc.

Division of Abbott Laboratories Inc.
www.sjm.com

Latest From St. Jude Medical Inc.

Market Brief: Innovation Will Drive 13% Growth In Global Transcatheter Mitral Valve Repair Market by 2023, Outpacing Growth Of TAVR

The transcatheter heart valve management products market will reach $6.7bn by 2023, driven by the rising prevalence of heart disease. Transcatheter aortic valve replacement (TAVR) procedures lead the market, but innovation and rising competition, including from companies in China and India, will fuel double-digit growth in the much smaller mitral valve repair market, dominated by Abbott's MitraClip.

Market Intelligence Innovation

Medtech Veteran Robert Ford Will Take Over As Abbott CEO From Miles White

Abbott’s current COO Robert Ford will become the company’s new CEO on 31 March, 2020. Miles White is stepping down after 21 years leading the diversified health-care products company.

Appointments Commercial

Acutus Announces Four Deals To Expand Its Reach Into Electrophysiology

Acutus announced a deal to acquire Rhythm Xience, and new strategic partnerships with Peerbridge Health, Cardiac Designs and MedFact, to offer more electrophysiology products that complement its AcQMap multi-electrode electrophysiology mapping catheter system.

Companies Deals

Heartburn: Yet Another Device-Maker Is Facing Cardiac Device Cybersecurity Worries – This Time, It's Medtronic

Medtronic cardiac devices are vulnerable to malicious hackers who could potentially not only intercept data between the patient and their provider, but also may be able to manipulate the implantable cardiac devices, possibly leading to serious adverse events and death. US FDA says patients should continue to use the devices as usual but should look out for telltale signs of an attack. Meanwhile, Medtronic claims it was aware of the issue and contends that patients shouldn't be concerned: “To date, no cyberattack, privacy breach, or patient harm has been observed," a spokesman says.

United States Cybersecurity
See All

Company Information

UsernamePublicRestriction

Register